No evidence of disease activity (NEDA) has been proposed as a new treatment goal in multiple sclerosis (MS). NEDA-3 status is defined as the absence of magnetic resonance imaging (MRI; new/enlarging/enhancing lesions and increased whole brain volume loss in NEDA-4) and clinical disease activity.
Objectives:
To investigate the persistence of NEDA status over long-term follow-up in MS patients treated with weekly intramuscular interferon beta-1a.
Methods:
We included 192 patients after the first demyelinating event suggestive of MS, that is, clinically isolated syndrome (CIS) and 162 relapsing-remitting MS (RRMS) patients.
Results:
NEDA-3 status was observed in 40.1% of CIS and 20.4% of RRMS patients after 1 year. After 4 years, 10.1% of CIS patients had NEDA-3 status. After 10 years, none of the RRMS patients had NEDA-3 status. Only 4.6% of CIS and 1.0% of RRMS patients maintained NEDA-4 status after 4 years. Loss of NEDA-3 status after the first year was associated with a higher risk of disability progression (hazard ratio (HR) = 2.3–4.0; p = 0.005–0.03) over 6 years.
Conclusions:
Despite intramuscular interferon beta-1a treatment, loss of NEDA status occurred in the vast majority of individuals. Loss of NEDA status during the first year was associated with disability progression over long-term follow-up; however, specificity for individual patient was low.
HavrdovaEGalettaSStefoskiD. Freedom from disease activity in multiple sclerosis. Neurology2010; 74(Suppl. 3): S3–S7.
2.
HavrdovaEGalettaSHutchinsonM. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: A retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol2009; 8(3): 254–260.
3.
GiovannoniGCookSRammohanK. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: A post-hoc and subgroup analysis. Lancet Neurol2011; 10(4): 329–337.
4.
GiovannoniGTurnerBGnanapavanS. Is it time to target no evident disease activity (NEDA) in multiple sclerosis?Mult Scler Relat Disord2015; 4(4): 329–333.
5.
BevanCJCreeBA. Disease activity free status: A new end point for a new era in multiple sclerosis clinical research?JAMA Neurol2014; 71(3): 269–270.
6.
HartungHPAktasO. Evolution of multiple sclerosis treatment: Next generation therapies meet next generation efficacy criteria. Lancet Neurol2011; 10(4): 293–295.
7.
NixonRBergvallNTomicD. No evidence of disease activity: Indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis. Adv Ther2014; 31(11): 1134–1154.
8.
ArnoldDLCalabresiPAKieseierBC. Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: Results from a randomized controlled trial in relapsing-remitting multiple sclerosis. BMC Neurol2014; 14: 240.
9.
RotsteinDLHealyBCMalikMT. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol2015; 72(2): 152–158.
10.
SormaniMPRioJTintoreM. Scoring treatment response in patients with relapsing multiple sclerosis. Multiple Scler2013; 19(5): 605–612.
11.
BermelRAYouXFouldsP. Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta. Ann Neurol2013; 73(1): 95–103.
12.
UherTBenedictRHHorakovaD. Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment. J Neurol Sci2014; 347(1–2): 229–234.
13.
KalincikTVaneckovaMTyblovaM. Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: A longitudinal cohort study. PLoS ONE2012; 7(11): e50101.
14.
HorakovaDZivadinovRWeinstock-GuttmanB. Environmental factors associated with disease progression after the first demyelinating event: Results from the multi-center SET study. PLoS ONE2013; 8(1): e53996.
15.
ZivadinovRChinJHorakovaD. Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: Results from the multi-center set study. J Neuroimmunol2014; 273(1–2): 58–64.
16.
ZivadinovRHavrdovaEBergslandN. Thalamic atrophy is associated with development of clinically definite multiple sclerosis. Radiology2013; 268(3): 831–841.
17.
HorakovaDZivadinovRWeinstock-GuttmanB. HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event. J Neuroimmunol2011; 236(1–2): 76–80.
18.
UherTHorakovaDBergslandN. MRI correlates of disability progression in patients with CIS over 48 months. Neuroimage Clin2014; 6: 312–319.
19.
UherTHorakovaDKalincikT. Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon beta-1a. Eur J Neurol2015; 22(7): 1113–1123.
20.
UherTHorakovaDTyblovaM. Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later. Multiple Scler. Epub ahead of print 11September2015. DOI: 10.1177/1352458515601903.
21.
UherTBlahova-DusankovaJHorakovaD. Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome. J Neurol2014; 261(9): 1735–1744.
22.
HavrdovaEZivadinovRKrasenskyJ. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. Multiple Scler2009; 15(8): 965–976.
23.
HorakovaDKalincikTDolezalO. Early predictors of non-response to interferon in multiple sclerosis. Acta Neurol Scand2012; 126(6): 390–397.
24.
KalincikTHorakovaDDolezalO. Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort. Clin Neurol Neurosurg2012; 114(7): 940–946.
25.
BergslandNHorakovaDDwyerMG. Subcortical and cortical gray matter atrophy in a large sample of patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol2012; 33(8): 1573–1578.
26.
ZivadinovRRudickRADe MasiR. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology2001; 57(7): 1239–1247.
27.
ComiGFilippiMWolinskyJS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging—Measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol2001; 49(3): 290–297.
28.
De StefanoNStromilloMLGiorgioA. Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. J Neurol Neurosurg Psychiatry. Epub ahead of print 22April2015. DOI: 10.1136/jnnp-2014-309903.
29.
ZivadinovRRederATFilippiM. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology2008; 71(2): 136–144.
30.
LublinFDCofieldSSCutterGR. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol2013; 73(3): 327–340.
31.
De StefanoNStromilloMLGiorgioA. Long-term assessment of no evidence of disease activity in relapsing-remitting MS. Neurology2015; 85(19): 1722–1723.
32.
UherTVaneckovaMSobisekL. Combining clinical and MRI predictors enhances prediction of 6-year disability after first clinical event suggestive of multiple sclerosis. Oral presentation at 31st congress of the European Committee for Treatment and Research in Multiple Sclerosis, Barcelona, 7–10 October 2015.
33.
SormaniMSignoriAStromilloM. Refining response to treatment as defined by the Modified Rio Score. Multiple Scler2013; 19(9): 1246–1247.
34.
NygaardGOCeliusEGde Rodez BenaventSA. A longitudinal study of disability, cognition and gray matter atrophy in early multiple sclerosis patients according to evidence of disease activity. PLoS ONE2015; 10(18.8): e0135974.
35.
ZeccaCDisantoGSormaniMP. Relevance of asymptomatic spinal MRI lesions in patients with multiple sclerosis. Multiple Scler. Epub ahead of print 12October2015. DOI: 10.1177/1352458515599246.
